Turner Investments LLC Sells 18,260 Shares of Achillion Pharmaceuticals, Inc. (ACHN)

Turner Investments LLC decreased its position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 21.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,420 shares of the biopharmaceutical company’s stock after selling 18,260 shares during the period. Turner Investments LLC’s holdings in Achillion Pharmaceuticals were worth $275,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Deschutes Portfolio Strategy LLC raised its stake in shares of Achillion Pharmaceuticals by 13.4% in the first quarter. Deschutes Portfolio Strategy LLC now owns 25,430 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 3,000 shares in the last quarter. Teza Capital Management LLC purchased a new stake in shares of Achillion Pharmaceuticals during the first quarter valued at $131,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Achillion Pharmaceuticals during the first quarter valued at $138,000. Canada Pension Plan Investment Board raised its stake in shares of Achillion Pharmaceuticals by 4.7% in the first quarter. Canada Pension Plan Investment Board now owns 35,800 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 1,600 shares in the last quarter. Finally, Pacad Investment Ltd. raised its stake in shares of Achillion Pharmaceuticals by 2.4% in the fourth quarter. Pacad Investment Ltd. now owns 37,800 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 900 shares in the last quarter. 77.85% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals, Inc. (ACHN) traded down 4.57% on Monday, hitting $4.80. The company’s stock had a trading volume of 2,588,285 shares. Achillion Pharmaceuticals, Inc. has a 1-year low of $3.15 and a 1-year high of $10.06. The company’s market capitalization is $656.27 million. The company has a 50 day moving average price of $3.87 and a 200-day moving average price of $4.08.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. During the same quarter in the prior year, the firm earned ($0.13) earnings per share. On average, equities analysts forecast that Achillion Pharmaceuticals, Inc. will post ($0.64) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Turner Investments LLC Sells 18,260 Shares of Achillion Pharmaceuticals, Inc. (ACHN)” was reported by Mideast Time and is the property of of Mideast Time. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.mideasttime.com/turner-investments-llc-sells-18260-shares-of-achillion-pharmaceuticals-inc-achn/1753567.html.

Several equities analysts have recently commented on the company. Leerink Swann raised Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the company from $4.00 to $6.00 in a report on Thursday, May 18th. Zacks Investment Research lowered Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 10th. Jefferies Group LLC reaffirmed a “hold” rating on shares of Achillion Pharmaceuticals in a report on Wednesday, April 26th. Maxim Group lowered their target price on Achillion Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, April 25th. Finally, Robert W. Baird upped their target price on Achillion Pharmaceuticals from $5.00 to $10.00 and gave the company an “outperform” rating in a report on Monday, April 24th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $9.22.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:ACHN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.